0000950170-24-080012.txt : 20240702
0000950170-24-080012.hdr.sgml : 20240702
20240702073003
ACCESSION NUMBER: 0000950170-24-080012
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240628
FILED AS OF DATE: 20240702
DATE AS OF CHANGE: 20240702
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Kathiresan Sekar
CENTRAL INDEX KEY: 0001864112
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40489
FILM NUMBER: 241092908
MAIL ADDRESS:
STREET 1: 500 TECHNOLOGY SQUARE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Verve Therapeutics, Inc.
CENTRAL INDEX KEY: 0001840574
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 824800132
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 201 BROOKLINE AVENUE
STREET 2: SUITE 601
CITY: BOSTON
STATE: MA
ZIP: 02215
BUSINESS PHONE: (978) 501-3026
MAIL ADDRESS:
STREET 1: 201 BROOKLINE AVENUE
STREET 2: SUITE 601
CITY: BOSTON
STATE: MA
ZIP: 02215
4
1
ownership.xml
4
X0508
4
2024-06-28
0001840574
Verve Therapeutics, Inc.
VERV
0001864112
Kathiresan Sekar
C/O VERVE THERAPEUTICS, INC.
201 BROOKLINE AVENUE, SUITE 601
BOSTON
MA
02215
true
true
false
false
Chief Executive Officer
false
Common Stock
2024-06-28
4
M
false
30000
2.87
A
351128
D
Common Stock
240997
I
Kathiresan Family 2021 Irrevocable Trust
Common Stock
80997
I
Sekar Kathiresan 2021 Irrevocable Trust
Stock Option (right to buy)
2.87
2024-06-28
4
M
false
30000
0
D
2030-09-15
Common Stock
30000
215308
D
Stock Option (right to buy)
2.87
2030-09-15
Common Stock
160000
160000
I
Sekar Kathiresan 2022 Annuity Trust
Stock Option (right to buy)
2.87
2030-09-15
Common Stock
200000
200000
I
Sekar Kathiresan 2023 Annuity Trust
Includes 4,918 shares of the Company's common stock acquired under the Verve Therapeutics, Inc. Amended and Restated 2021 Employee Stock Purchase Plan.
The remaining shares underlying this option, which was granted on September 16, 2020, vest in equal monthly installments until September 16, 2024.
The shares underlying the option were fully vested when transferred.
/s/ Andrew Ashe, as Attorney-in-Fact for Sekar Kathiresan
2024-07-02